Page last updated: 2024-10-22

amifostine anhydrous and Pseudomyxoma Peritonei

amifostine anhydrous has been researched along with Pseudomyxoma Peritonei in 1 studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Pseudomyxoma Peritonei: A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bouhadjari, N1
Gabato, W1
Calabrese, D1
Msika, S1
Keita, H1

Other Studies

1 other study available for amifostine anhydrous and Pseudomyxoma Peritonei

ArticleYear
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:2

    Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P

2016